Navigation Links
Medimetriks Pharmaceuticals, Inc. Begins Operations
Date:5/13/2008

Bradley Pharmaceuticals Founder and Senior Management Form Company

Specializing in Dermatology and Podiatry Markets

FAIRFIELD, N.J., May 13 /PRNewswire/ -- Medimetriks Pharmaceuticals, Inc. announced today that it commenced operations. The newly-formed Company, led by the founder and the key Senior Management Team of the former Bradley Pharmaceuticals (NYSE: BDY), will develop, license and commercialize innovative prescription products for the Dermatology and Podiatry marketplaces. The Company is aggressively pursuing licensing opportunities, company and product acquisitions and initiating the development of a series of brands that will fill unmet needs in the marketplace. Medimetriks' objective is to build a robust product portfolio and become a leading Dermatology and Podiatry specialty company.

Bradley Pharmaceuticals was acquired earlier this year by Nycomed for approximately $350MM. Bradley's Doak Dermatologics Division, which represented approximately 80% of Bradley's revenue, was a leading dermatology company and the largest independent pharmaceutical marketer to the podiatry specialty. Bradley Glassman, the former Senior Vice President of Sales and Marketing for Bradley, will serve as President and CEO of Medimetriks Pharmaceuticals, Brent Lenczycki as Chief Financial Officer and Alan Goldstein as Executive Vice President, Business Development. Daniel Glassman, the former President and CEO of Bradley, will serve as Medimetriks' Chairman of the Board.

"We have an experienced management team that was an important part of Bradley's success," stated Daniel Glassman. "We also have added a strong support team that will allow Medimetriks to achieve both short and long term success. Medimetriks' talented staff demonstrates a tremendous ability to execute with discipline and shares a commitment to creating a meaningful Company that will enhance patient care."

Bradley Glassman said, "We will leverage our core expertise of identifying and delivering important and effective brands in the therapeutic markets that we know so well. In building the Bradley business, we developed long-standing relationships with leading physicians in both the Dermatology and Podiatry specialties. We look forward to working with these physicians and building brands that serve the interests of both their practices and their patients."

The Company is located at 363 Route 46 West, Suite 106, Fairfield, NJ 07004-2402. Please visit the Medimetriks website at http://www.medimetriks.com .


'/>"/>
SOURCE Medimetriks Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
2. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
4. Jazz Pharmaceuticals, Inc. to Announce First Quarter Results on May 13, 2008
5. Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
6. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
7. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
8. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
9. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
10. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
11. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... innovative medical technologies, services and solutions to the healthcare market. The company's primary ... various distribution, manufacturing, sales and marketing strategies that are necessary to help companies ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
Breaking Biology Technology:
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):